Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial
Eric Lawitz, Jay P. Lalezari, Tarek Hassanein, Kris V. Kowdley, Fred F. Poordad, Aasim M. Sheikh, Nezam H. Afdhal, David E. Bernstein, Edwin DeJesus, Bradley Freilich, David R. Nelson, Douglas T. Dieterich, Ira M. Jacobson, Donald Jensen, Gary A. Abrams, Jama M. Darling, Maribel Rodriguez-Torres, K. Rajender Reddy, Mark S. Sulkowski, Natalie H. BzowejRobert H. Hyland, Hongmei Mo, Ming Lin, Michael Mader, Robert Hindes, Efsevia Albanis, William T. Symonds, Michelle M. Berrey, Andrew Muir
Research output: Contribution to journal › Article › peer-review
272Scopus
citations
Fingerprint
Dive into the research topics of 'Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial'. Together they form a unique fingerprint.